GlassScriptPhysician profile
Kathryn A Sabo
NPI 1942200035
$5,214.40
in general payments reported to CMS, 2019-2025
28 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $2,302 · 2023: $1,009 · 2024: $714 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,482.09 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Relievant Medsystems, INC. | $1,258.61 | 2022 | |
| Abbvie INC. | $611.43 | 2022-2025 | |
| Pfizer INC. | $303.64 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $227.01 | 2022-2025 | Ztlido |
| Vertos Medical, INC. | $140.57 | 2022-2024 | Mild Device Kit |
| Biohaven Pharmaceuticals, INC. | $137.10 | 2021 | |
| Painteq LLC | $135.57 | 2021-2022 | |
| Spr Therapeutics, INC | $123.38 | 2023-2025 | Sprint Pns System |
| Depuy Synthes Sales INC. | $108.01 | 2022-2025 | Orthovisc, Monovisc |
| Ibsa Pharma INC. | $96.45 | 2021-2024 | Tirosint, Licart, Tirosint |
| International Rehabilitative Sciences, INC | $92.68 | 2023-2024 | Rs 4i Plus Sequential Stimulator |
| Vertex Pharmaceuticals Incorporated | $87.22 | 2024-2025 | |
| Saluda Medical Americas, INC. | $49.04 | 2025 | Evoke |
| Biohaven Pharmaceutical Holding Company LTD. | $49.01 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $44.92 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $32.35 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $28.34 | 2021 | |
| Averitas Pharma INC. | $23.26 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $22.87 | 2024 | Ingrezza |
| Allergan, INC. | $22.40 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.88 | 2023 | Exparel, Zilretta, Iovera |
| Medtronic, INC. | $20.65 | 2022 | |
| Collegium Pharmaceutical, INC. | $20.12 | 2023 | Nucynta |
| Novo Nordisk INC | $20.07 | 2023 | Wegovy |
| Fidia Pharma USA INC. | $19.71 | 2022 | |
| Nevro Corp. | $18.10 | 2022 | |
| Abbott Laboratories | $17.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Sabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.